Scholarlink

<p>In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月27日

查看全文
  • Damien Vasseur,
  • Samuel Abbou,
  • Ludovic Lacroix,
  • Laurence Lamant,
  • Noémie Pata-Merci,
  • David Sibon,
  • Francesco Facchinetti,
  • Marc Deloger,
  • Floriane Braye,
  • Véronique Minard-Colin,
  • Laurence Brugières,
  • Etienne Rouleau,
  • Luc Friboulet,
  • Charlotte Rigaud

摘要

In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.